agents used during induction therapy were prednisone, vincristine, L-asparaginase, intrathecal methotrexate, and additional doxorubicm in some patients.
Patients
were followed at least once a month throughout the treatment period and once or twice a year after discontinuation of therapy.
Two patients were lost to follow-up because of emigration; both were in primary remission lasting 7 and 36 months, respec-
tively.
The closing date of follow-up was October 31, 1986. The mean follow-up time was 69 months (range 22 to 140 months). prognosis.
The 5-year event-free survivals for children with blast clearance 10 days (n = 138), 11 to 13 days (n = I 1), and >13 days (n = 9)
were 60%, 36%, and 17%, respectively (Fig 1 ) For personal use only. on November 15, 2017. by guest www.bloodjournal.org From
